Jared Holz, Mizuho Securities healthcare sector strategist, joins 'The Exchange' to discuss Insmed's lung drug being greenlit ...

AbbVie unveiled a $195 million investment to expand active pharmaceutical ingredient manufacturing in the U.S. Bloomberg reported that BlinkRx, a company that has Donald Trump Jr. on its board, just ...

Stifel raised the firm’s price target on Insmed (INSM) to $145 from $121 and keeps a Buy rating on the shares following FDA’s recent approval of ...

The Food and Drug Administration (FDA) has approved Brinsupri ™ (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients aged 12 years and older.

For more on Prasad’s return, go here; for a “Matt’s Take” on Prasad, go here; for the latest on investors’ attitudes toward ...

TheStreet. Good morning. The market is open. Investors are digesting the release of key economic data this morning, namely the Producer Price Index (PPI) and Initial / Continuing Jobless Claims. Both ...